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Reticulocyte enumeration was described for the first time 
in the late 1940s. Until the early 1980s, it was performed 
exclusively by microscopic examination of supravital 
stained peripheral blood smears. Besides pathophysiologic 
conditions, technical artifacts and human subjectivity 
during the microscopic analysis are the primary causes of 
the compromised accuracy of manual reticulocyte counts. In 
the early 1950s, Kozenow and Mai1 were the first to report an 
enumeration method for reticulocytes, based on fluorescence 
microscopy with an RNA/DNA-specific fluorochrome (acridine 
orange). Although fluoresce techniques offer some practical 
advances over light microscopy, automated reticulocyte 
enumeration by flow cytometry was proven to be even better. 
It is faster, technically easier to perform, more objective, 
easily automated, and less labor-intensive when compared 
to manual slide-based techniques. Rather than reducing 
the human interaction, it reduces the sample’s turn-around 
time, and therefore increases cost-efficiency, especially for 
high throughput analyses. Furthermore, flow cytometry also 
provides accurate information on the age distribution of the 
reticulocyte population.
The first decade of the 2000s brought the dawn of a new 
era in reticulocyte enumeration, when methods using existing 
hematology analyzers were developed. Currently, blood 
analyzers offer integrated and user-friendly flow cytometry 
platforms, which do not require specially trained technical 
staff in order to perform reticulocyte enumeration, as was 
necessary in the case of separate flow devices. 
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Several fluorochromes, such as acridine orange, propidium 
iodide, ethidium bromide, thioflavin, and auramine were 
initially used in reticulocyte enumeration by flow cytometry. 
A great improvement of the counting accuracy was achieved 
through the development of the thioflavin T-analogue (thiazole 
orange [TO]), whose excitation occurs in the visible region (λ 
= 488 nm) and is specific for reticulocyte labeling. This made 
flow cytometry even more practical; nowadays, Food and Drug 
Administration-approved TO reagent kits are widely available to 
clinical laboratories, and automated reticulocyte enumeration 
tests are a standard routine. Rather than merely counting 
reticulocytes, flow cytometry also evaluates reticulocyte 
maturation based on the RNA content. Young or immature 
reticulocytes are highly fluorescent (high RNA content), while 
maturing reticulocytes have medium fluorescence intensity, 
and older reticulocytes have low fluorescence (low RNA 
content). The mean fluorescence of a TO-stained reticulocyte 
population, the reticulocyte maturation index (RMI), is a useful 
clinical indicator of erythropoietic activity and a valuable 
addition to the conventional reticulocyte count. 
In 2013, a survey of the College of American Pathologists (RT, 
RT-04, 2013) observed that, of 1,055 participating laboratories, 
302 used Sysmex XE 2100 (coefficients of variation [CV]: 17.7%), 
15 used Sysmex XE 2100C (CV: 13.1%), 413 used Sysmex-5000 
(CV: 16.5%), 60 used Sysmex XN-Series (CV: 16.3%); and 267 
used Sysmex XT 2000 (CV: 15.3%) hematology analyzers for the 
index determination of immature reticulocytes. The average 
CV suggests that clinicians should include approximately 20% 
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of technical variation into their considerations before making 
any decision. 
In this issue of the Revista Brasileira de Hematologia 
e Hemoterapia, Wollmann et al. describe a method using 
fluorescence reticulocyte intensity (low [LFR], medium [MFR], 
and high [HFR] fluorescence reticulocyte indexes) instead 
of RMI in order to improve the characterization of iron 
deficiency anemia (IDA).2 The authors report that the small 
number of patients in the sample is sufficient to establish a 
positive correlation between reticulocyte immaturity and IDA. 
Similarly, Kojima et al.3 were able to establish an increase in 
the reticulocyte count, compared to the control group, by 
examining only eight patients with IDA. Conversely, Cortellazzi 
et al.4 demonstrated that erythroid expansion in sickle cell 
diseases (Hb SS, Hb SC, and Hb S/ β-thalassemia) leads to 
an increased release of immature reticulocytes from the 
bone marrow. No difference with respect to any reticulocyte 
parameter was observed between the β-thalassemia and 
IDA groups. In fact, the RMI showed a significant correlation 
between the total iron-binding capacity (TIBC) and ferritin,5 
reflecting the activity of the bone marrow and erythropoiesis. 
In order to better classify IDA anemia, the hemoglobin 
content of reticulocytes (CHr) is a very important and highly 
sensitive parameter. When patients with low levels of bone 
marrow iron stores (considering only those patients with 
MCV less than 100 fL) were examined, the receiver operator 
curve analysis of CHr, ferritin, transferrin saturation, and MCV 
demonstrated that CHr has the highest overall sensitivity and 
specificity for an accurate prediction of the absence of bone 
marrow iron stores.6 The previously mentioned College of 
American Pathologists7 survey from 2013 also revealed that 665 
laboratories used the same equipment for the RMI, and that 
the mean CV observed was less than 3% (CHr in pictograms).
In conclusion, extensive evidence has been accumulated 
suggesting that reticulocyte parameters (flow cytometry 
counting, RMI, and CHr) are useful for a variety of purposes, 
e.g. accurately diagnosing anemia patients, assessing the 
regenerative activity after anemia treatment, monitoring 
patients receiving recombinant human erythropoietin, or 
recovering from chemotherapy or bone marrow transplants. 
For these reasons, clinical laboratories should both record and 
report these parameters routinely in the future.
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